Medlab Clinical Limited
(ASX:MDC) has been granted a 20 year Australian patent for its anti-depression product NRGBiotic.
Te company says NRGBiotic has demonstrated significant enhancements for depression sufferers, adding to its commercial potential.
Applications for patents in the United States, Europe and two Asian countries are also underway.
According to the World Health Organisation, 350 million people world wide suffer from depression.
The company says to be granted a patent Medlab needed to show uniqueness, usefulness and effectiveness.
Shares in Medlab Clinical Limited
(ASX:MDC) are trading down 2.54 per cent to 58c
